CAS: 6640-50-2; 1,2,3,4-Tetrahydro-8-Hydroxyquinoline

上下游产品

CAS号148-24-3 8-羟基喹啉 | CAS号53899-17-5 8-甲氧基-1,2,3,4-四氢喹啉 | CAS号938-33-0 8-甲氧基喹啉 | CAS号90-04-0 邻氨基苯甲醚 | CAS号7732-18-5 水 | CAS号7664-93-9 硫酸 | CAS号148-24-3 8-羟基喹啉 | CAS号72696-21-0 5,6-dihydro-4H-... | CAS号676255-10-0 N-B°C-8-羟基四氢喹啉

📜5-氯-8-羟基喹啉置于palladium 10% On Activated Carbon,氢气体系中,用 四氢呋喃,甲醇 作为反应溶剂,20.0 °C,101.33 Kpa 条件下,反应 24.5H,以72%的收率获得产物8-羟基-1,2,3,4-四氢喹啉
参考文献:Ddi-6 的鉴定和合成,一种能够激活秀丽隐杆线虫和小鼠精子的喹啉类似物
标题:Ddi-6 的鉴定和合成,一种能够激活秀丽隐杆线虫和小鼠精子的喹啉类似物
摘要:精子激活是雄配子能够受精的重要过程.由于秀丽隐杆线虫的过程在体外很容易重现,因此该生物体可作为研究它的极好模型.c. 线虫体内精子激活发生在精子发生过程中.包含在精子细胞内的膜细胞器 (Mo) 与质膜融合,导致其内容物的细胞外释放和一些对受精必不可少的蛋白质从 Mo 膜重新定位到精子表面.有趣的是,这些细胞学变化在顶体反应期间在小鼠精子中表现出类似的表现,这也代表了精子激活的一种形式,促使我们假设秀丽隐杆线虫和小鼠共享一个共同的精子激活机制.为了探索这一点,我们首先筛选了一个化学库来识别激活秀丽隐杆线虫的化合物精子.因为一种名为 Ddi-6 的喹啉类似物似乎是一种候选精子激活剂,我们合成了它以用于进一步分析.这涉及市售的 5-氯-8-羟基喹啉的直接脱氯和氢解,这两个步骤都是产生 1,2,3,4-四氢-8-羟基喹啉的关键步骤,我们随后将磺酰胺基团引入到该化合物中.当线虫精子细胞单独用溶剂或新合成的
DOI:10.1248/cpb.C21-00127

专利信息

专利号:US-5283336-A
优先权日:1992-09-08
标 题 :Method for preparation of 7-hydroxy-1,2,3,4-tetrahydroquinoline from 1,2,3,4-tetrahydroquinoline
发明人：FIELD GEORGE; HAMMOND PETER R
权利人:US ARMY
摘要:Methods for the efficient preparation of 7-hydroxy-1,2,3,4-tetrahydroquinoline include a first method in which the acylation of m-aminophenol obtains a lactam which is reduced to give the desired quinoline and a second method in which tetrahydroquinoline is nitrated and hydrogenated and then hydrolyzed to obtain the desire quinoline. 7-hydroxy-1,2,3,4-tetrahydroquinoline is used in the efficient synthesis of four lasing dyes of the rhodamine class.

专利号:CN-113717098-A
优先权日:2021-09-08
标题 :A method for the synthesis of tetrahydroquinoline compounds with non-hydrogen participation in selective catalytic hydrogenation of quinoline compounds

专利号:US-10988466-B2
优先权日:2017-03-23
标题:Heterocyclic derivatives useful as SHP2 inhibitors
发明人：MA CUNBO; GAO PANLIANG; HU SHAOJING; XU ZILONG; HAN HUIFENG; WU XINPING; KANG DI
权利人:JACOBIO PHARMACEUTICALS CO LTD
摘要:This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.